Form 4: Black Diamond Therapeutics Director Acquires Shares in Lieu of Cash Compensation

Director Ali Behbahani acquired 3,007 shares of Black Diamond Therapeutics common stock in lieu of cash compensation for annual services.

Summary

• On September 20, 2024, Ali Behbahani, a director of Black Diamond Therapeutics, Inc., acquired 3,007 shares of common stock.
• The shares were issued in lieu of cash compensation for annual services as a non-employee director, according to the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy.
• The price per share was $4.78, based on the closing market price of the Issuer's common stock on September 19, 2024.
• Following the transaction, Mr. Behbahani directly owns 57,584 shares of common stock.
• Mr. Behbahani is also a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P., which in turn is the sole general partner of New Enterprise Associates 16, L.P. ('NEA 16').
• NEA 16 is the direct beneficial owner of 4,448,757 securities.
• Mr. Behbahani disclaims beneficial ownership of the securities held by NEA 16 in which he has no pecuniary interest.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. A director taking shares in lieu of cash is generally a good sign, but the transaction is relatively small and part of a pre-existing compensation plan.

Positives

• A director's decision to take shares in lieu of cash compensation could be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Director share acquisitions are common and are usually viewed positively by the market.

Stakeholder Impact

• The transaction could have a slightly positive impact on shareholders, as it signals confidence from a director.

Key Dates